Motavizumab

DB06310InvestigationalProtein Based Therapies

Investigated for use/treatment in viral infection and pediatric indications.

Mechanism: Motavizumab is a second generation, ultra-potent, affinity-matured, humanized mAb derived from palivizumab that reduces replication of Respiratory Syncytial Virus (RSV), a pathogen which causes lower respiratory tract disease.
Curator reviewed
Primary indication: Investigated for use/treatment in viral infection and pediatric indications.Curator reviewed
Code names: MEDI-524

Resolves to

Compound

Clinical / RWD

Targets

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

12Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 14 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Motavizumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.